News Release

Smokers less likely to survive a heart attack

No difference found in hypertensive and non-hypertensive individuals

Peer-Reviewed Publication

Experimental Biology

Said Khatib, PhD

image: Said Khatib, PhD view more 

Credit: Said Khatib, PhD

PHILADELPHIA (April 2, 2022)—Smokers have a lower chance of surviving a heart attack than non-smokers, according to new data compiled by researchers at Jordan University of Science and Technology in Irbid. Levels of Alpha-1 Anti Trypsin (A1AT)—a protein in the liver that protects the body’s tissues—in smokers were “significantly less” than in non-smokers, the study found. Yet, no difference was detected in hypertensive and non-hypertensive individuals. The researchers will present their findings in person at the American Physiological Society’s (APS) annual meeting at Experimental Biology 2022 in Philadelphia.

 

Approximately 1.5 million heart attacks and strokes happen annually in the U.S., according to the U.S. Department of Health and Human Services’ Division for Heart Disease and Stroke Prevention. It is believed A1AT could offer protection to cardiac tissue when it is released during a heart attack.  

 

“The aim of this study was to compare the plasma levels of A1AT released in smokers and non-smokers, and between hypertensive and non-hypertensive individuals after an attack,” reported Said Khatib, PhD, a co-author of the study.

 

The human study was conducted in 29 adult men and 11 adult women through blood samples drawn within one, four, 24, 48 and 96 hours of a heart attack diagnosis. Participants were divided into four groups of smokers and non-smokers, and hypertensive and non-hypertensive.

 

Researchers believe that maintaining appropriate levels of A1AT in smokers during a heart attack will improve their chances of survival.  

 

NOTE TO JOURNALISTS: To schedule an interview with a member of the research team, and/or request abstract R5502, “Time course of blood level of alpha-1 antitrypsin over 96 hours in smokers and hypertensive patients after acute myocardial infarction,” please contact the APS Media Relations or call 301.634.7314. Find more research highlights in the APS Newsroom.

 

About Experimental Biology 2022

Experimental Biology is the annual meeting of five societies that explores the latest research in physiology, anatomy, biochemistry and molecular biology, investigative pathology and pharmacology. With a mission to share the newest scientific concepts and research findings shaping clinical advances, the meeting offers an unparalleled opportunity for global exchange among scientists who represent dozens of scientific areas, from laboratory to translational to clinical research.

 

About the American Physiological Society

Physiology is a broad area of scientific inquiry that focuses on how molecules, cells, tissues and organs function in health and disease. The American Physiological Society connects a global, multidisciplinary community of more than 10,000 biomedical scientists and educators as part of its mission to advance scientific discovery, understand life and improve health. The Society drives collaboration and spotlights scientific discoveries through its 16 scholarly journals and programming that support researchers and educators in their work.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.